{
  "N/R/U": null,
  "Applicant": "Amgen Inc.",
  "BLA Number": "125518",
  "Proprietary Name": "Imlygic",
  "Proper Name": "Talimogene laherparepvec",
  "BLA Type": "351(a)",
  "Strength": "100 MILLION PFU/ML",
  "Dosage Form": "For Injection",
  "Route of Administration": "Intralesional",
  "Product Presentation": "Single-Dose Vial",
  "Marketing Status": "Rx",
  "Licensure": "Licensed",
  "Approval Date": "27-Oct-15",
  "Ref. Product Proper Name": " ",
  "Ref. Product Proprietary Name": null,
  "Supplement Number": "0",
  "Submission Type": "Original",
  "License Number": "1080",
  "Product Number": "1",
  "Center": "CBER",
  "Date of First Licensure": null,
  "Exclusivity Expiration Date": null,
  "First Interchangeable Exclusivity Exp. Date": null,
  "Ref. Product Exclusivity Exp. Date": null,
  "Orphan Exclusivity Exp. Date": "27-Oct-22"
}